Evidence method
Level · gp.fundamentals.debt_to_revenue
38126.92% · OPTIONAL · NOT_ENOUGH_HISTORY
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
CUE · Jun 30, 2022
Cue Biopharma, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0000950170-22-014747General Corporate
Evidence method
Level · gp.fundamentals.capex_revenue_ratio
250.00% · OPTIONAL · VALID
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
-49415.38% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
-99.05% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
-50346.15% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
36892.31% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
8880.77% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History29 statesSelf-history eligible
Sep 30, 20216/6 normalizedLevel 3Dec 31, 20216/6 normalizedLevel 3Mar 31, 20226/7 normalizedLevel 3Jun 30, 20226/7 normalizedLevel 3Sep 30, 20226/7 normalizedLevel 3Dec 31, 20226/7 normalizedLevel 3Mar 31, 20236/7 normalizedLevel 3Jun 30, 20236/7 normalizedLevel 3Sep 30, 20236/7 normalizedLevel 3Dec 31, 20236/7 normalizedLevel 3Mar 31, 20247/7 normalizedLevel 3Jun 30, 20247/7 normalizedLevel 3Sep 30, 20247/7 normalizedLevel 3Dec 31, 20246/6 normalizedLevel 3Mar 31, 20256/6 normalizedLevel 3Jun 30, 20256/6 normalizedLevel 3Sep 30, 20256/6 normalizedLevel 3Dec 31, 20256/6 normalizedLevel 3Mar 31, 20266/6 normalizedLevel 3Jun 30, 20266/6 normalizedLevel 4
Period transition
What moved in the state?
- Previous
- 986.10%
- Current
- 38126.92%
- Delta
- 37140.82%
- Previous
- 2.70%
- Current
- 250.00%
- Delta
- 247.30%
- Previous
- -1157.30%
- Current
- -49415.38%
- Delta
- -48258.08%
- Previous
- -35.61%
- Current
- -99.05%
- Delta
- -63.44%
- Previous
- -1423.80%
- Current
- -50346.15%
- Delta
- -48922.35%
- Previous
- 1008.20%
- Current
- 36892.31%
- Delta
- 35884.11%
- Previous
- 301.10%
- Current
- 8880.77%
- Delta
- 8579.67%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · CUE Fundamental State →Has State · Cue Biopharma, Inc. →Transitioned To · CUE Fundamental State →Transitioned To · CUE BALANCE_SHEET_LEVERAGE_INCREASED →Transitioned To · CUE CAPEX_INTENSITY_INCREASED →Transitioned To · CUE CASH_GENERATION_DECREASED →Transitioned To · CUE GROWTH_DECREASED →Transitioned To · CUE PROFITABILITY_DECREASED →Transitioned To · CUE R_AND_D_INTENSITY_INCREASED →Transitioned To · CUE SBC_INTENSITY_INCREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.